New applications of Clioquinol in the treatment of inflammation disease by directly targeting arginine 335 of NLRP3

doi: 10.1016/j.jpha.2024.101069

• Peipei Chen^a,b,c,d , 
• Yunshu Wang^a,b,c,d , 
• Huaiping Tang^a,b,c,d , 
• Chao Zhou^a,b,c,d , 
• Zhuo Liu^a,b,c,d , 
• Shenghan Gao^a,b,c,d , 
• Tingting Wang^{c ,  ,}  , 
• Yun Xu^{a,b,c,d ,  ,}  , 
• Sen-Lin Ji^{a,b,c,d ,  ,} 

• a Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China;

• b State Key Laboratory of Pharmaceutical Biotechnology and Institute of Translational Medicine for Brain Critical Diseases, Nanjing University, Nanjing, China;

• c Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, China;

• d Nanjing Neurology Clinical Medical Center, Nanjing, China;

• e State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Jiangsu Key Laboratory of Molecular Medicine, Division of Immunology, Medical School, Nanjing University, Nanjing, China